vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Smith Douglas Homes Corp. (SDHC). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $260.4M, roughly 1.1× Smith Douglas Homes Corp.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 1.4%, a 95.0% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 17.3%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
ACAD vs SDHC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $260.4M |
| Net Profit | $273.6M | $3.5M |
| Gross Margin | 90.8% | 19.9% |
| Operating Margin | 6.1% | 6.5% |
| Net Margin | 96.3% | 1.4% |
| Revenue YoY | 9.4% | -9.4% |
| Net Profit YoY | 90.3% | -14.3% |
| EPS (diluted) | $1.61 | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $260.4M | ||
| Q3 25 | $278.6M | $262.0M | ||
| Q2 25 | $264.6M | $223.9M | ||
| Q1 25 | $244.3M | $224.7M | ||
| Q4 24 | $259.6M | $287.5M | ||
| Q3 24 | $250.4M | $277.8M | ||
| Q2 24 | $242.0M | $220.9M | ||
| Q1 24 | $205.8M | $189.2M |
| Q4 25 | $273.6M | $3.5M | ||
| Q3 25 | $71.8M | $2.1M | ||
| Q2 25 | $26.7M | $2.4M | ||
| Q1 25 | $19.0M | $2.7M | ||
| Q4 24 | $143.7M | $4.1M | ||
| Q3 24 | $32.8M | $5.3M | ||
| Q2 24 | $33.4M | $3.6M | ||
| Q1 24 | $16.6M | $3.0M |
| Q4 25 | 90.8% | 19.9% | ||
| Q3 25 | 92.2% | 21.0% | ||
| Q2 25 | 92.2% | 23.2% | ||
| Q1 25 | 91.7% | 23.8% | ||
| Q4 24 | 91.6% | 25.5% | ||
| Q3 24 | 92.5% | 26.5% | ||
| Q2 24 | 92.5% | 26.7% | ||
| Q1 24 | 88.8% | 26.1% |
| Q4 25 | 6.1% | 6.5% | ||
| Q3 25 | 12.8% | 6.6% | ||
| Q2 25 | 12.2% | 7.7% | ||
| Q1 25 | 7.9% | 8.7% | ||
| Q4 24 | 59.1% | 10.4% | ||
| Q3 24 | 12.6% | 14.2% | ||
| Q2 24 | 12.6% | 11.7% | ||
| Q1 24 | 7.4% | 11.3% |
| Q4 25 | 96.3% | 1.4% | ||
| Q3 25 | 25.8% | 0.8% | ||
| Q2 25 | 10.1% | 1.1% | ||
| Q1 25 | 7.8% | 1.2% | ||
| Q4 24 | 55.4% | 1.4% | ||
| Q3 24 | 13.1% | 1.9% | ||
| Q2 24 | 13.8% | 1.7% | ||
| Q1 24 | 8.0% | 1.6% |
| Q4 25 | $1.61 | $0.39 | ||
| Q3 25 | $0.42 | $0.24 | ||
| Q2 25 | $0.16 | $0.26 | ||
| Q1 25 | $0.11 | $0.30 | ||
| Q4 24 | $0.86 | $0.50 | ||
| Q3 24 | $0.20 | $0.58 | ||
| Q2 24 | $0.20 | $0.40 | ||
| Q1 24 | $0.10 | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $12.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $86.7M |
| Total Assets | $1.6B | $557.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $12.7M | ||
| Q3 25 | $258.0M | $14.8M | ||
| Q2 25 | $253.6M | $16.8M | ||
| Q1 25 | $217.7M | $12.7M | ||
| Q4 24 | $319.6M | $22.4M | ||
| Q3 24 | $155.1M | $23.7M | ||
| Q2 24 | $177.1M | $17.3M | ||
| Q1 24 | $204.7M | $32.8M |
| Q4 25 | $1.2B | $86.7M | ||
| Q3 25 | $917.3M | $82.2M | ||
| Q2 25 | $822.4M | $80.0M | ||
| Q1 25 | $765.2M | $76.9M | ||
| Q4 24 | $732.8M | $73.6M | ||
| Q3 24 | $577.2M | $68.4M | ||
| Q2 24 | $516.7M | $62.1M | ||
| Q1 24 | $464.0M | $59.7M |
| Q4 25 | $1.6B | $557.6M | ||
| Q3 25 | $1.3B | $571.6M | ||
| Q2 25 | $1.2B | $570.2M | ||
| Q1 25 | $1.1B | $513.9M | ||
| Q4 24 | $1.2B | $475.9M | ||
| Q3 24 | $976.9M | $460.1M | ||
| Q2 24 | $914.1M | $429.3M | ||
| Q1 24 | $855.1M | $401.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $9.8M |
| Free Cash FlowOCF − Capex | — | $8.7M |
| FCF MarginFCF / Revenue | — | 3.4% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | -0.18× | 2.77× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-36.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $9.8M | ||
| Q3 25 | $74.3M | $22.8M | ||
| Q2 25 | $64.0M | $-28.9M | ||
| Q1 25 | $20.3M | $-34.9M | ||
| Q4 24 | $40.4M | $5.5M | ||
| Q3 24 | $63.2M | $22.9M | ||
| Q2 24 | $25.0M | $39.0K | ||
| Q1 24 | $29.1M | $-9.3M |
| Q4 25 | — | $8.7M | ||
| Q3 25 | $73.9M | $21.4M | ||
| Q2 25 | — | $-31.1M | ||
| Q1 25 | — | $-35.9M | ||
| Q4 24 | — | $4.8M | ||
| Q3 24 | $63.2M | $22.3M | ||
| Q2 24 | — | $-2.1M | ||
| Q1 24 | — | $-9.7M |
| Q4 25 | — | 3.4% | ||
| Q3 25 | 26.5% | 8.2% | ||
| Q2 25 | — | -13.9% | ||
| Q1 25 | — | -16.0% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | 25.2% | 8.0% | ||
| Q2 24 | — | -1.0% | ||
| Q1 24 | — | -5.1% |
| Q4 25 | — | 0.4% | ||
| Q3 25 | 0.1% | 0.5% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | — | 1.0% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | -0.18× | 2.77× | ||
| Q3 25 | 1.03× | 10.70× | ||
| Q2 25 | 2.40× | -12.24× | ||
| Q1 25 | 1.07× | -13.01× | ||
| Q4 24 | 0.28× | 1.33× | ||
| Q3 24 | 1.93× | 4.28× | ||
| Q2 24 | 0.75× | 0.01× | ||
| Q1 24 | 1.76× | -3.12× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
SDHC
| Southeast | $164.7M | 63% |
| Central | $95.8M | 37% |
